INmune Bio Inc.NASDAQ: INMB

INmune Bio Reports Significant EEG Improvement in Alzheimer’s Patients Treated with XPro™

· Issued by INmune Bio Inc. via GlobeNewswire

Patients with Alzheimer’s Disease show improvement in brainwaves following 4 weeks of XPro™ therapy.

Boca Raton, Florida, March 05, 2024 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company targeting microglial activation and neuroinflammation as a cause of Alzheimer’s disease (AD) reports significant improvements in electroencephalography (EEG), a biomarker of brain function, in patients with moderate to severe Alzheimer’s Disease treated with XPro™ for four weeks.

Patients who received weekly XPro™ treatment for four weeks had a statistically significant increase in Alpha wave frequency and power (p

INmune Bio Inc. on 6ix

Story so far

Earlier from INmune Bio

Later from INmune Bio

All INmune Bio news releases